Trasylol Anti-Bleeding Drug Proves High Surgery Death Risk
Thursday, May 15th, 2008In November, Bayer pulled it’s anti-bleeding drug off the market due to reports from studies that it caused up to 22,000 deaths from people who were taking it. Now, a recent study’s results released on Wednesday confirms that Trasylol indeed is a definite risk to those who took it for its clotting properties when undergoing open heart surgery.
The New England Journal of Medicine released studies that an incredible 6% of those who took Traysol died within 30 days of their surgeries, and the drug itself increases a mortality rate of up to 50%. Compared to other medications that were used previously to Trasylol’s release, this is a death rate increase of 2%. This study proves that this next-generation medication actually does more harm than good for those undergoing surgical procedures.
Incredibly, this prescription medication for bleeding costs $1,400 per dose, or $1,390 more than the older, safer drug; bringing into question the company’s motives for releasing the drug so quickly into market and its reluctance to admit it’s fault.
While it is noncommittal to whether its medication will return to the market, Bayer is now fighting off 83 lawsuits related to Trasylol prescription drug usage with more likely to follow.
http://online.wsj.com/article/SB121080806023693335.html
Source: Wall Street Journal
Subscribe to our daily news feed